Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H.

Cancer Immunol Immunother. 2018 Nov 14. doi: 10.1007/s00262-018-2274-1. [Epub ahead of print]

PMID:
30430205
2.

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity.

Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, Aoyama N, Nishida Y, Tsuboi A, Oka Y, Nishida S, Nakata J, Hosen N, Oji Y, Sugiyama H.

Oncotarget. 2018 Sep 25;9(75):34132-34141. doi: 10.18632/oncotarget.26139. eCollection 2018 Sep 25.

3.

Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.

Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Shimodaira S, Okamoto M, Sugiyama H, Koido S.

Oncol Lett. 2018 Aug;16(2):2682-2692. doi: 10.3892/ol.2018.8961. Epub 2018 Jun 13.

4.

GCH1 mutations in dopa-responsive dystonia and Parkinson's disease.

Yoshino H, Nishioka K, Li Y, Oji Y, Oyama G, Hatano T, Machida Y, Shimo Y, Hayashida A, Ikeda A, Mogushi K, Shibagaki Y, Hosaka A, Iwanaga H, Fujitake J, Ohi T, Miyazaki D, Sekijima Y, Oki M, Kusaka H, Fujimoto KI, Ugawa Y, Funayama M, Hattori N.

J Neurol. 2018 Aug;265(8):1860-1870. doi: 10.1007/s00415-018-8930-8. Epub 2018 Jun 14.

PMID:
29948246
5.

Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.

Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N.

Mov Disord. 2018 Sep;33(9):1488-1492. doi: 10.1002/mds.27365. Epub 2018 May 14.

PMID:
29756366
6.

WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.

Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H.

Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21.

PMID:
29322496
7.

Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease.

Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N.

Neurology. 2018 Jan 30;90(5):e404-e411. doi: 10.1212/WNL.0000000000004888. Epub 2018 Jan 3.

8.

The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A.

Nat Med. 2017 Dec;23(12):1436-1443. doi: 10.1038/nm.4431. Epub 2017 Nov 6.

PMID:
29106400
9.

Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.

Oka Y, Tsuboi A, Nakata J, Nishida S, Hosen N, Kumanogoh A, Oji Y, Sugiyama H.

Oncol Res Treat. 2017;40(11):682-690. doi: 10.1159/000481353. Epub 2017 Oct 18. Review.

10.

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, Vandenbosch I, Verlinden A, Gadisseur AP, Schroyens WA, Muylle L, Vermeulen K, Maes MB, Deiteren K, Malfait R, Gostick E, Lammens M, Couttenye MM, Jorens P, Goossens H, Price DA, Ladell K, Oka Y, Fujiki F, Oji Y, Sugiyama H, Berneman ZN.

Blood. 2017 Oct 12;130(15):1713-1721. doi: 10.1182/blood-2017-04-780155. Epub 2017 Aug 22.

11.

Regulation of Stemness in Carcinoma Cells.

Hao J, Unternaehrer J, Cui X, Cheng N, Oji Y.

Stem Cells Int. 2017;2017:7681769. doi: 10.1155/2017/7681769. Epub 2017 Jul 27. No abstract available.

12.

Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease.

Saiki S, Hatano T, Fujimaki M, Ishikawa KI, Mori A, Oji Y, Okuzumi A, Fukuhara T, Koinuma T, Imamichi Y, Nagumo M, Furuya N, Nojiri S, Amo T, Yamashiro K, Hattori N.

Sci Rep. 2017 Aug 4;7(1):7328. doi: 10.1038/s41598-017-06767-y.

13.

Limb-Shaking Transient Ischemic Attack Induced by Middle Cerebral Artery Dissection after Lung Surgery.

Taniguchi D, Oji Y, Ueno Y, Hirayama S, Fukui M, Miyamoto N, Yamashiro K, Tanaka R, Suzuki K, Hattori N.

J Stroke Cerebrovasc Dis. 2017 Oct;26(10):e197-e198. doi: 10.1016/j.jstrokecerebrovasdis.2017.06.049. Epub 2017 Jul 26.

PMID:
28756145
14.

Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.

Nakata J, Nakae Y, Kawakami M, Morimoto S, Motooka D, Hosen N, Fujiki F, Nakajima H, Hasegawa K, Nishida S, Tsuboi A, Oji Y, Oka Y, Kumanogoh A, Sugiyama H.

Br J Haematol. 2018 Jul;182(2):287-290. doi: 10.1111/bjh.14768. Epub 2017 May 23. No abstract available.

PMID:
28542830
15.

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.

Takashima S, Oka Y, Fujiki F, Morimoto S, Nakajima H, Nakae Y, Nakata J, Nishida S, Hosen N, Tatsumi N, Mizuguchi K, Hashimoto N, Oji Y, Tsuboi A, Kumanogoh A, Sugiyama H.

Future Sci OA. 2016 Oct 3;2(4):FSO96. doi: 10.4155/fsoa-2015-0008. eCollection 2016 Dec.

16.

Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.

Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Oji Y, Oka Y, Sugiyama H.

Stem Cell Investig. 2016 Dec 9;3:90. doi: 10.21037/sci.2016.11.08. eCollection 2016. Review.

17.

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.

Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, Chiba Y, Izumoto S, Elisseeva O, Ichinohasama R, Sakamoto J, Morita S, Nakajima H, Takashima S, Nakae Y, Nakata J, Kawakami M, Nishida S, Hosen N, Fujiki F, Morimoto S, Adachi M, Iwamoto M, Oka Y, Yoshimine T, Sugiyama H.

Int J Cancer. 2016 Sep 15;139(6):1391-401. doi: 10.1002/ijc.30182. Epub 2016 May 31.

18.

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.

Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakano K, Kinoshita H, Okumura A, Fujioka Y, Urakawa R, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Miyoshi E, Hirata T, Kumanogoh A, Sugiyama H, Hosen N.

PLoS One. 2016 Mar 24;11(3):e0152326. doi: 10.1371/journal.pone.0152326. eCollection 2016.

19.

An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.

Kondo K, Fujiki F, Nakajima H, Yatsukawa E, Morimoto S, Tatsumi N, Nishida S, Nakata J, Oka Y, Tsuboi A, Hosen N, Oji Y, Sugiyama H.

J Immunother. 2016 Apr;39(3):127-39. doi: 10.1097/CJI.0000000000000114.

PMID:
26938946
20.

Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides.

Nakajima H, Murakami Y, Morii E, Akao T, Tatsumi N, Odajima S, Fukuda M, Machitani T, Iwai M, Kawata S, Hojo N, Oka Y, Sugiyama H, Oji Y.

Oncol Rep. 2016 Apr;35(4):1959-66. doi: 10.3892/or.2016.4589. Epub 2016 Jan 22.

PMID:
26820500
21.

A Zbtb7a proto-oncogene as a novel target for miR-125a.

Hojo N, Tatsumi N, Moriguchi N, Matsumura A, Morimoto S, Nakata J, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Hayashi S, Sugiyama H, Oji Y.

Mol Carcinog. 2016 Dec;55(12):2001-2009. doi: 10.1002/mc.22446. Epub 2015 Dec 29.

PMID:
26713860
22.

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells.

Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Hosen N.

PLoS One. 2015 Dec 11;10(12):e0144594. doi: 10.1371/journal.pone.0144594. eCollection 2015.

23.

Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.

Sawada A, Inoue M, Kondo O, Yamada-Nakata K, Ishihara T, Kuwae Y, Nishikawa M, Ammori Y, Tsuboi A, Oji Y, Koyama-Sato M, Oka Y, Yasui M, Sugiyama H, Kawa K.

Pediatr Blood Cancer. 2016 Feb;63(2):234-41. doi: 10.1002/pbc.25792. Epub 2015 Oct 15.

PMID:
26469989
24.

[III. Peptide vaccination therapy against brain tumors].

Hashimoto N, Kagawa N, Arita H, Tsuboi A, Oka Y, Oji Y, Sugiyama H, Yoshimine T.

Gan To Kagaku Ryoho. 2015 Jun;42(6):687-9. Japanese. No abstract available.

PMID:
26242006
25.

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.

Tatsumi N, Hojo N, Sakamoto H, Inaba R, Moriguchi N, Matsuno K, Fukuda M, Matsumura A, Hayashi S, Morimoto S, Nakata J, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Sugiyama H, Oji Y.

PLoS One. 2015 Jun 19;10(6):e0130578. doi: 10.1371/journal.pone.0130578. eCollection 2015.

26.

Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Tatsumi N, Hojo N, Yamada O, Ogawa M, Katsura Y, Kawata S, Morii E, Sakamoto H, Inaba R, Tsuda A, Fukuda I, Moriguchi N, Hasuwa H, Okabe M, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Sugiyama H, Oji Y.

Oncogene. 2016 Feb 25;35(8):1003-14. doi: 10.1038/onc.2015.154. Epub 2015 May 11.

PMID:
25961914
27.

Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.

Nakae Y, Oka Y, Fujiki F, Morimoto S, Kamiya T, Takashima S, Nakata J, Nishida S, Nakajima H, Hosen N, Tsuboi A, Kyo T, Oji Y, Mizuguchi K, Kumanogoh A, Sugiyama H.

Cancer Immunol Immunother. 2015 Jul;64(7):791-804. doi: 10.1007/s00262-015-1683-7. Epub 2015 Apr 3.

PMID:
25835542
28.

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.

Hashimoto N, Tsuboi A, Kagawa N, Chiba Y, Izumoto S, Kinoshita M, Kijima N, Oka Y, Morimoto S, Nakajima H, Morita S, Sakamoto J, Nishida S, Hosen N, Oji Y, Arita N, Yoshimine T, Sugiyama H.

Cancer Immunol Immunother. 2015 Jun;64(6):707-16. doi: 10.1007/s00262-015-1674-8. Epub 2015 Mar 14.

PMID:
25772149
29.

Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.

Katsuhara A, Fujiki F, Aoyama N, Tanii S, Morimoto S, Oka Y, Tsuboi A, Nakajima H, Kondo K, Tatsumi N, Nakata J, Nakae Y, Takashima S, Nishida S, Hosen N, Sogo S, Oji Y, Sugiyama H.

Anticancer Res. 2015 Mar;35(3):1251-61.

PMID:
25750272
30.

WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.

Wu C, Wang S, Xu C, Tyler A, Li X, Andersson C, Oji Y, Sugiyama H, Chen Y, Li A.

Cell Physiol Biochem. 2015;35(2):647-62. doi: 10.1159/000369726. Epub 2015 Jan 28.

31.

Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair.

Oji Y, Tatsumi N, Kobayashi J, Fukuda M, Ueda T, Nakano E, Saito C, Shibata S, Sumikawa M, Fukushima H, Saito A, Hojo N, Suzuki M, Hoshikawa T, Shimura T, Morii E, Oka Y, Hosen N, Komatsu K, Sugiyama H.

Mol Carcinog. 2015 Dec;54(12):1758-71. doi: 10.1002/mc.22248. Epub 2014 Nov 21.

PMID:
25418835
32.

The Wilms' Tumor Gene WT1 - 17AA/- KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model.

Yamanouchi K, Ohta T, Liu Z, Oji Y, Sugiyama H, Shridhar V, Matsumura S, Takahashi T, Takahashi K, Kurachi H.

Transl Oncol. 2014 Oct 24;7(5):580-9. doi: 10.1016/j.tranon.2014.07.008. eCollection 2014 Oct.

33.

Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.

Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Nakae Y, Takashima S, Oji Y, Oka Y, Kumanogoh A, Sugiyama H.

Expert Rev Hematol. 2014 Oct;7(5):671-81. doi: 10.1586/17474086.2014.953925. Epub 2014 Sep 4. Review.

PMID:
25186852
34.

Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.

Hatano T, Funayama M, Kubo SI, Mata IF, Oji Y, Mori A, Zabetian CP, Waldherr SM, Yoshino H, Oyama G, Shimo Y, Fujimoto KI, Oshima H, Kunii Y, Yabe H, Mizuno Y, Hattori N.

Neurobiol Aging. 2014 Nov;35(11):2656.e17-2656.e23. doi: 10.1016/j.neurobiolaging.2014.05.025. Epub 2014 Jun 2.

35.

Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.

Andersson C, Oji Y, Ohlson N, Wang S, Li X, Ottander U, Lundin E, Sugiyama H, Li A.

Cancer Med. 2014 Aug;3(4):909-18. doi: 10.1002/cam4.244. Epub 2014 Apr 8.

36.

The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.

Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S, Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T, Shimizu Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S, Nonomura N, Yoshimine T, Okumura M, Morii E, Maeda H, Nishida S, Hosen N, Tsuboi A, Oka Y, Sugiyama H.

Int J Oncol. 2014 May;44(5):1461-9. doi: 10.3892/ijo.2014.2318. Epub 2014 Mar 4.

37.

Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.

Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Kitagawa T, Eguchi H, Wada H, Nagano H, Nakata J, Nakae Y, Hosen N, Oji Y, Tanaka T, Kawase I, Kumanogoh A, Sakamoto J, Doki Y, Mori M, Ohkusa T, Tajiri H, Sugiyama H.

J Immunother. 2014 Feb-Mar;37(2):105-14. doi: 10.1097/CJI.0000000000000020.

38.

Longitudinally extensive transverse myelitis with intramedullary metastasis of small-cell lung carcinoma: an autopsy case report.

Nishioka K, Tanaka R, Tsutsumi S, Shimura H, Oji Y, Saeki H, Yasumoto Y, Ito M, Hattori N, Urabe T.

Case Rep Neurol Med. 2013;2013:305670. doi: 10.1155/2013/305670. Epub 2013 Dec 22.

39.

Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis.

Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, Sugiyama H, Yoshimine T.

Anticancer Res. 2014 Jan;34(1):61-7.

PMID:
24403445
40.

Spontaneous spinal subarachnoid hemorrhage after severe coughing: a case report.

Oji Y, Noda K, Tokugawa J, Yamashiro K, Hattori N, Okuma Y.

J Med Case Rep. 2013 Dec 23;7:274. doi: 10.1186/1752-1947-7-274.

41.

In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.

Nakata J, Nakano K, Okumura A, Mizutani Y, Kinoshita H, Iwai M, Hasegawa K, Morimoto S, Fujiki F, Tatsumi N, Nakajima H, Nakae Y, Nishida S, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Kumanogoh A, Hosen N.

Leukemia. 2014 Jun;28(6):1316-25. doi: 10.1038/leu.2013.374. Epub 2013 Nov 13.

PMID:
24336127
42.

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine.

Maeda T, Hosen N, Fukushima K, Tsuboi A, Morimoto S, Matsui T, Sata H, Fujita J, Hasegawa K, Nishida S, Nakata J, Nakae Y, Takashima S, Nakajima H, Fujiki F, Tatsumi N, Kondo T, Hino M, Oji Y, Oka Y, Kanakura Y, Kumanogoh A, Sugiyama H.

Blood Cancer J. 2013 Aug 2;3:e130. doi: 10.1038/bcj.2013.29. No abstract available.

43.

Cerebral infarction in a case of Parry-Romberg syndrome.

Tomizawa Y, Tanaka R, Sekiguchi K, Oji Y, Tanaka Y, Yamashiro K, Hattori N.

J Stroke Cerebrovasc Dis. 2014 Feb;23(2):393-4. doi: 10.1016/j.jstrokecerebrovasdis.2013.02.015. Epub 2013 May 8.

PMID:
23664460
44.

HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.

Lin Y, Fujiki F, Katsuhara A, Oka Y, Tsuboi A, Aoyama N, Tanii S, Nakajima H, Tatsumi N, Morimoto S, Tamanaka T, Tachino S, Hosen N, Nishida S, Oji Y, Kumanogoh A, Sugiyama H.

J Immunother. 2013 Apr;36(3):159-70. doi: 10.1097/CJI.0b013e3182873581.

PMID:
23502763
45.

Reversible focal cerebral cortical lesions in a patient with heat stroke.

Fuse A, Yamashiro K, Oji Y, Furuya T, Noda K, Hattori N, Okuma Y.

Intern Med. 2013;52(3):377-80. Epub 2013 Feb 1.

46.

Functional human Th17 clones with WT1-specific helper activity.

Tachino S, Fujiki F, Oka Y, Tsuboi A, Morimoto S, Lin YH, Tamanaka T, Kondo K, Nakajima H, Nishida S, Hosen N, Oji Y, Kumanogoh A, Sugiyama H.

Cancer Immunol Immunother. 2013 Apr;62(4):801-10. doi: 10.1007/s00262-012-1385-3. Epub 2012 Dec 29.

PMID:
23275045
47.

Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.

Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, Hosen N, Nishida S, Lin YH, Tachino S, Akatsuka Y, Kuzushima K, Oji Y, Kumanogoh A, Sugiyama H.

Anticancer Res. 2012 Dec;32(12):5201-9.

PMID:
23225417
48.

WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.

Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, Nakatsuka S, Morita S, Sakamoto J, Sugiyama H, Kimura T.

J Cancer Res Clin Oncol. 2013 Mar;139(3):457-63. doi: 10.1007/s00432-012-1348-2. Epub 2012 Nov 18.

PMID:
23160854
49.

Identification of a Wilms' tumor 1-derived immunogenic CD4(+) T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes.

Anguille S, Fujiki F, Smits EL, Oji Y, Lion E, Oka Y, Berneman ZN, Sugiyama H.

Leukemia. 2013 Mar;27(3):748-50. doi: 10.1038/leu.2012.248. Epub 2012 Aug 29. No abstract available.

PMID:
22929521
50.

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.

Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K, Mugitani A, Ichihara H, Aoyama Y, Nishida S, Tsuboi A, Fujiki F, Tatsumi N, Nakajima H, Hino M, Kimura T, Yata K, Abe M, Oka Y, Oji Y, Kumanogoh A, Sugiyama H.

Leukemia. 2012 Sep;26(9):2135-41. doi: 10.1038/leu.2012.80. Epub 2012 Mar 20.

PMID:
22430638

Supplemental Content

Support Center